EINPRESSWIRE

Non-Alcoholic Steatohepatitis (NASH) Market Expected to Reach $21,478 Million by 2025

Non-alcoholic steatohepatitis (NASH) market provides an in-depth analysis size along with the current trends and future estimations.

PORTLAND, OREGON, UNITED STATES, November 24, 2023 / EINPresswire.com/ -- Non-alcoholic steatohepatitis (NASH) market was valued at $1,179 million in 2017, and is expected to reach $21,478 million by 2025, growing at a CAGR of 58.4% from 2021 to 2025. Non-alcoholic steatohepatitis (NASH), is a common liver disease, often called as silent liver disease. It is asymptomatic until its later stages, and thus many patients are unaware of their condition. NASH is projected to lead the cause of liver transplantation in the U.S. in the coming years. Some major factors such as higher prevalence of NASH, expected launch of pipeline drugs, and higher number of unmet needs drive the growth of this market. However, poor diagnosis of NASH due to the lack of ideal diagnostic technologies limit the growth of the NASH market.

GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) MARKET
OPPORTUNITIES AND FORECASTS, 2018-2025

Global non-alcoholic steatohepatitis (NASH) market is expected to reach $21,478 million by 2025.
Growing at a CAGR of 58.4% (2021-2025)

Non-alcoholic steatohepatitis (NASH) industry 2030

▢▢▢▢ ▢▢ ▢▢▢ ▢▢▢▢▢▢▢▢ :
Gemphire Therapeutics Inc., Novartis International AG, Cadila Healthcare Ltd., Genfit SA, Conatus Pharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Galmed Pharmaceuticals Ltd., Allergan Plc (Tobira Therapeutics Inc.), Gilead Sciences, Inc., Shire plc

▢▢▢▢▢▢▢▢ ▢▢▢▢▢▢ ▢▢▢▢▢▢ https://www.alliedmarketresearch.com/request-sample/224

At present, there is no FDA-approved drug available in the market for the treatment of NASH. Lifestyle interventions are the first-line approach to manage patients with NASH. Based on drug type, the market is segmented into vitamin E & pioglitazone, ocaliva, elafibranor, and selonsertib & cenicriviroc. Vitamin E & pioglitazone segment contributes majorly due to effectiveness in a treatment of steatosis, inflammation, hepatocyte ballooning, and scarring in NASH patients.

Based on sales channel, the market is segmented into hospital pharmacy, online provider, and retail pharmacy. At present, the retail pharmacy segment is major revenue generator, and is estimated to show dominance during the forecast period due to the patient convenience and strong presence of retail pharmacies around the world. However, the online provider segment is projected to exhibit the fastest market growth due to rise in awareness of online pharmacies and increase in preference for online purchase of drugs over the traditional methods.

खरीद पूछताछ करें: https://www.alliedmarketresearch.com/purchase-enquiry/224

North America accounted approximately one half of the global market share in 2017 and is expected to remain dominant throughout the forecast period. Major factors that driving the market growth in North America are, early diagnosis of the disease, higher prevalence of disease, and strong presence of pipeline drugs. On the other hand, Asia-Pacific is expected to experience the highest CAGR of 62.62% during the forecast period primarily due to growth in prevalence of NASH along with the increase in prevalence of diabetes & obesity and rise in awareness of NASH among the patients. Furthermore, growth in number of R&D activities, development in diagnostic technologies, and increase in healthcare spending is expected to drive the NASH market in Asia-Pacific region.

एवेन्यू- एक सब्सक्रिप्शन-आधार लाइब्रेरी (प्रीमियम ऑन-डिमांड, सब्सक्रिप्शन-आधार मूल्य निर्धारण मॉडल) प्रदान करता है की विशेषताएं निम्नलिखित हैं:

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

आप इस अवसर का लाभ उठाएंगे और ग्राहकों के लिए अधिक मूल्य बनाने में सक्षम होंगे. कृपया नीचे क्लिक करें, सदस्यता लिंक करें: https://www.alliedmarketresearch.com/library-access

एलाइड मार्केट रिसर्च कंपनी:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive

& Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of the domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Analytics LLP
+ +1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/670651709